injectable and ophthalmic pharmaceutical company
We market and manufacture a growing portfolio of FDA-approved medicines, including several generic alternatives, in the United States. Our products include both injectable and ophthalmic prescription medicines.
Filling the Gap
Dawah Pharmaceuticals will produce sterile injectable medications that are currently in demand in the marketplace. We are currently submitting our first product to the FDA, expected to reach the market in early 2025.
Future State of the Art Aseptic Production Facility
Construction of our manufacturing facility is assumed to begin in 2025 and will take through 2027 to complete.
Our Approach
The first 8 products will initially be produced through independent third-party manufacturers (CMO’s) until we can complete the construction of our own production facility. Those products will initially come to market from 2025 through 2026.
ABOUT
Dawah Pharmaceuticals is a privately held company concentrated on developing and commercializing clinically critical therapies across various dosage forms and parenteral therapeutic categories, including generics and 505(b)(2) drugs.
Disclaimer: The content on this website has been prepared by the Founders of Dawah Pharmaceuticals and is general background information about Dawah Pharmaceuticals' strategic vision in this presentation. This information is given in the summary form and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not consider your investment objectives, financial situation or needs. Before acting on any information, you should consider the appropriateness of the information having regard to these matters, any relevant offer document and, you should seek independent financial advice. All securities and financial products or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk. This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to Dawah Pharmaceuticals businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements. Dawah Pharmaceuticals does not undertake any obligation to release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Dawah Pharmaceuticals control. Past performance is not a reliable indication of future performance. All rights reserved. The material may not be reproduced or distributed, in whole or in part, without the prior written permission of Dawah Pharmaceuticals Inc.